S852 E-Poster Viewing

Results: Mr. T.J, a 64-year-old man with a 10-year history of PD, was treated with levodopa, amantadine, and pramipexole. He developed depression a year ago, managed with fluoxetine. Recently, he was admitted to the psychiatric ward due to severe behavioral disturbances, including hetero-aggressiveness towards his wife.

Psychiatric assessment revealed a delusional syndrome with themes of jealousy and persecution towards his wife, accompanied by a hallucinatory syndrome primarily characterized by auditory hallucinations that appeared 2 years ago.

A neurological examination identified an amnesic syndrome that preceded the onset of delusions, raising concerns about the differential diagnosis between psychosis and dementia in the context of PD with the added consideration of the iatrogenic effects of his Parkinson's treatment.

In collaboration with neurologists, we adjusted the treatment regimen by tapering off amantadine and pramipexole while maintaining levodopa. We introduced 5 mg of olanzapine, which led to a favorable clinical response. After two weeks, Mr. T.J was considered stable enough for discharge. Improvements included a reduction in delusional ideation and a decrease in the frequency and severity of auditory hallucinations.

Conclusions: This case highlights the complexity of managing psychiatric symptoms in Parkinson's disease, particularly the challenge of differentiating between psychosis and dementia. The positive outcome following medication adjustments underscores the importance of a multidisciplinary approach in addressing both motor and psychiatric symptoms in PD patients.

Disclosure of Interest: None Declared

EPV1130

The Journey of Gender Identity in the Elderly: Needs and Challenges

L. M. Carrasqueira¹*, B. Wildenberg², P. Esteves², F. Tavares³, B. Araújo⁴, J. Brás⁵ and M. Coroa²

¹Psychiatry , ULS Região de Leiria, Leiria; ²Psychiatry, ULS Coimbra, Coimbra; ³ULS Algarve- Unidade de Faro, Faro, Portugal; ⁴Psychiatry, ULS Algarve- Unidade de Faro, Faro and ⁵ULS Coimbra, Coimbra, Portugal

*Corresponding author. doi: 10.1192/j.eurpsy.2025.1726

Introduction: Gender identity issues in the elderly are often overlooked in psychiatric practice. Older transgender and gender-diverse adults face significant barriers, including social isolation, stigma, and limited access to gender-affirming care. These challenges, coupled with healthcare discrimination and gatekeeping, negatively impact mental health outcomes, often leaving this population underserved in healthcare systems.

Objectives: The aim is to identify the challenges transgender and gender-diverse elderly individuals face in accessing appropriate medical care and to explore how these barriers impact their overall health and well-being. Additionally, the objective is to propose strategies to improve both the mental health and general healthcare outcomes for this vulnerable group, ensuring that their specific needs are addressed within healthcare systems.

Methods: A narrative review of the literature was conducted using PubMed, ResearchGate, and Medline databases. Search included combinations of the terms "gender identity," "geriatic psychiaty"

and "gender dysphoria. Studies were selected based on their relevance to understanding the mental health and healthcare needs of elderly transgender and gender-diverse individuals.

Results: The review revealed that elderly individuals with gender identity concerns experience higher levels of depression, anxiety, and social isolation. Historical discrimination and healthcare disparities significantly impact their well-being. Studies indicate that increased risks for dementia, linked to factors such as cardiovascular disease and sexually transmitted infections, further heighten their vulnerability. Moreover, there are significant gaps in gender-affirming care within geriatic services. Healthcare providers often lack the training necessary to address the specific needs of older transgender adults, leading to delays or denials in appropriate care.

Conclusions: This review highlights that transgender and genderdiverse older adults remain a population often overlooked in psychiatric and geriatric care. Recognizing the importance of tailored care for this population is essential, as well as training healthcare providers and implementing gender-affirming treatments to ensure inclusive, equitable care that meets their specific needs.

Disclosure of Interest: None Declared

EPV1131

Delirium in a geriatric patient with Parkinson's disease, management and outcomes: a case report

I. Contreras Pérez¹*, A. Jurado Arévalo¹, M. P. Vargas Melero¹, I. Caparrós del Moral¹, R. Carrillo Molina¹ and F. Vílchez Español¹

¹Psiquiatría, Hospital Neurotraumatológico, Jaén, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2025.1727

Introduction: Up to 40% of patients diagnosed with Parkinson's disease (PD) may experience a psychotic episode during the course of the disease, with antiparkinsonian medications being the main cause. Frequently, aging is associated with a higher risk of comorbid delirium in this population.

Objectives: To analyze the treatment strategy for delirium in a geriatric patient with Parkinson's disease.

Methods: An 88-year-old male patient, diagnosed with Parkinson's disease for 12 years, was admitted to the Acute Psychiatry Hospitalization Unit due to a treatment-resistant confusional state. He presented fluctuating symptoms characterized by verbal and physical hetero-aggressiveness, visual illusions and hallucinations, as well as delusional ideas of harm, control, and mystical-religious content. The patient exhibited significant psychological distress, refused to eat, and had erratic medication adherence.

Results: Following a comprehensive organic assessment and treatment of intercurrent conditions, a readjustment of dopaminergic medication was performed, and quetiapine was introduced (up to 900 mg/day), with a partial response. Subsequently, the doses of quetiapine were reduced, and ziprasidone was introduced, achieving total remission of symptoms with good tolerance (quetiapine 450 mg/day, ziprasidone 80 mg/day, levodopa/ carbidopa 150 mg/day).

Conclusions: Following pharmacological recommendations for managing delirium, initial treatment with quetiapine (first-line) was established. Subsequently, clozapine (second-line) was introduced, achieving a better response and cessation of symptoms. This case highlights the complexity of managing delirium in geriatric